Market research reports on: Pharmaceutical manufacture, cancer, oncology, prevention and treatment, therapeutics, vaccines, clinical studies, drug delivery, immunology, immunotherapy and others.Let's Connect
This report is designed to investigate recent years of performance of pharmaceutical and biopharmaceutical companies with respect to return on investment (ROI) in research and development (R&D), and to discuss ways that companies are trying to improve ROI through 2024. Investigation will include Country/Regional market trends with top areas of return, 2014-2024. This report also looks at which companies are already using artificial intelligence (AI) and machine learning (ML) to successfully compete globally.
The global pediatric market should grow from $92.6 billion in 2019 to reach $116.6 billion by 2024 at a compound annual growth rate (CAGR) of 4.7% for the period of 2019-2024.
The global cannabis market should grow from $25.6 billion in 2019 to $77.6 billion by 2024 at a compound annual growth rate (CAGR) of 24.8% for the period of 2019-2024.
This report on Over-the-Counter (OTC) drugs and dietary supplement products market highlights primary healthcare and its various parameters such as the drafting of rules and regulations for OTC drugs and dietary supplements, the number of drugs classified, self-care awareness among consumers and the size of distribution networks, OTC drugs and dietary supplements manufacturers. BCC Research analyzed key categories and regions to determine the present and future OTC drugs and dietary supplement products market status and forecasted market growth.
This report provides information on significant drug launches in 2019. The study provides an overview of each drug, scientific summaries, pharmacodynamics, pharmacokinetics and clinical trial information, disease backgrounds, analysis of the market, competitors and company profiles of manufacturers. The objective of this study is to present a comprehensive analysis of the current market and its future direction.
The global market for communicable disease should grow from $57.7 billion in 2019 to $69.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.8% for the period of 2019-2024.
This report presents a perspective on the adoption of continuous manufacturing technologies by pharmaceuticals, the role of the FDA and implications for the generics sector.
The global market for neurology should grow from $33.3 billion in 2019 to $39.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.5% for the period of 2019-2024.
The report provides a detailed description of autoimmune responses and possible ways that drug development can augment immune responses so as to improve antitumor activity and reduce off target effect.This report will assess the latest developments in the IL-2 research and development and explore the novel strategies companies are adopting to augment immune response and avoid off target effects in a wide range of conditions including, metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), Type 1 diabetes (T1D), as a prophylaxis post-transplant and allergic conditions.What's coming: There are more than 200 studies underway evaluating IL-2 based therapies either as a monotherapy or in combination. The key products and companies that we believe are worth watching in this space are summarized.
The “Market at a Glance Pharmaceuticals” provides an access to all the market share analysis segments of the best-selling and key pharmaceutical reports of BCC Research. This report is a destination for the competitive landscape in the markets that hold a significant stand in the pharmaceuticals sector. Company profiles for all the notable manufacturers in the global pharmaceutical industry are provided as a part of this report.
Posttranslational modifications hit prime time in the pharma industry. There probably isn’t a medium sized biopharmaceutical that does not have an active program ongoing, and certainly all of the big pharma companies are running multiple programs, and collaborations, for what we might have previously termed “undruggable targets”. Many of these are for highly unmet needs in neurodegeneration. The properties of the structure that forms between a target, a degrader and an E3 ligase, are under intense investigation. Minor changes affect how the drugs work - this can explain how promiscuous target-binding payloads can achieve super selectivity when transformed into a degrader. These minor alterations can also render the molecule complex not only ineffective, but sometimes toxic. However, clinical results are beginning to write a compellingly effective story – the long and winding history of research into the ubiquitin proteasome may well have more blockbusters in store for us. And cures in a once overlooked corner of the cell machinery architecture.
The global colorectal cancer therapeutics market should reach $18.5 billion by 2023 from $13.7 billion in 2018 at a compound annual growth rate (CAGR) of 6.1% for the period 2018 to 2023.
The global market for drugs of abuse (DOA) testing should grow from $3.5 billion in 2018 to $4.6 billion by 2023 with a compound annual growth rate (CAGR) of 5.6% for the period of 2018-2023.
The global market for laboratory animal models should grow from $5.9 billion in 2018 to $7.8 billion by 2023, increasing at a compound annual growth rate (CAGR) of 5.6% for the period of 2018-2023.
2018 Pharmaceuticals Research Review provides a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision making.
The global market for laboratory automation systems and processes should grow from $21.1 billion in 2018 to reach $29.2 billion by 2023 at a compound annual growth rate (CAGR) of 6.8% for the period of 2018-2023.
The global market for in vitro toxicity testing should grow from $7.4 billion in 2018 to reach $10.4 billion by 2023 at a compound annual growth rate (CAGR) of 7.1% for the period of 2018-2023.
The global high-throughput screening (HTS) market should reach $21.1 billion by 2023 from $14.4 billion in 2018 at a compound annual growth rate (CAGR) of 7.9% for the period 2018-2023.
The global market for blood cancer therapeutics should grow from $38.5 billion in 2018 to $64.8 billion by 2023 at a compound annual growth rate (CAGR) of 11.0% from 2018 to 2023.
The global market for brain tumor therapeutics should grow from $1.1 billion in 2018 to reach $2.0 billion by 2023 at a compound annual growth rate (CAGR) of 12.9% for the period of 2018-2023.
The global cancer therapeutics market should grow from $128.1 billion in 2018 to $182.0 billion by 2023 at a compound annual growth rate (CAGR) of 7.3% for the period of 2018-2023.
The global market for CRO's across the clinical trial process should grow from $45.5 billion in 2017 to reach $72.3 billion by 2022 at a compound annual growth rate (CAGR) of 9.7% for the period of 2017-2022.
The global market for opioid drugs should reach $29.8 billion by 2023 from $26.4 billion in 2018 at a compound annual growth rate (CAGR) of 2.5% for the period of 2018-2023.
The global antibiotics market should reach $55.8 billion by 2023 from $38.3 billion in 2018 at a compound annual growth rate (CAGR) of 7.8% for the period of 2018-2023.
The global market for lung cancer therapeutics should grow from $17.9 billion in 2018 to $26.3 billion by 2023, increasing at a compound annual growth rate (CAGR) of 8.0% from 2018 to 2023.
- Detailed overview and an up-to-date analysis of the global markets for drugs of abuse (DOA) testing technologies
- Analyses of the global market trends, with historic market revenue for 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the upcoming market potential for DOA testing industry along with a detailed analysis of the competitive environment, industry trends, opportunities and penetration of emerging technologies within the marketplace
- Estimation of the actual market size and revenue forecast for the global drug abuse testing market in USD million values, and its corresponding market share analysis based on the product, sample type, drug type, testing type, end user, and region
- Technology assessment of the current and possible future legislation affecting the market in the U.S. and other emerging economies, and their influence in the market developments
- Statistical information covering drug abuse along with its trends as well as drug classes across the key geographic regions
- A comparative study and Porter’s Five Forces analysis considering both the micro and macro environmental factors prevailing in the market for drugs of abuse testing
- Review of the patents granted and patent applications on DOA testing and related technologies
- Identification of the major stakeholders and analysis of the company competitive landscape based on their recent market developments, financial performance, and segmental revenues
- Descriptive company profiles of the leading global players
The current report provides detailed information of top 50 Bestselling pharmaceutical drugs in the global market. This report also highlights current and future market potential of Pharmaceutical Industry along with a detailed analysis of regulatory scenario, technological advancements that impacts market growth.
This report presents an overview of the global market outlook for psychedelic drugs. Using 2021 as the base year, the report provides estimated market data for the forecast period 2022 through 2027. The report analyzes the industry structure, market dynamics, and supply chain analysis, regulatory landscape within the industry.
This report aims to provide a comprehensive study of the market size of global epigenetic therapeutics market. Current and historical market revenues can be estimated based on the product type and by region.